Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/62—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving uric acid

Definitions

• the invention is an assay device useful in determining the presence and concentration of uric acid in a liquid sample, such as urine.
• Dry phase analyte assay test strips also known as "one-step” assays, requiring only addition of sample to the test strip
• analytes such as glucose and hormones in body fluids
• Important advantages of such test strips include low cost, ease of use, relatively accurate assays and a short response time.
• the manufacture of test strips for one-step detection of uric acid has been hampered by thermal instability of the uricase enzyme reagent, whose activity can be quickly impaired under common conditions of manufacturing, storage and use (especially with fluids samples of variable pH, such as urine).
• uric acid is typically measured in blood or serum using multiple step liquid sample assay protocols.
• the invention consists of a one-step test strip and methods for its use in detecting the presence and concentration of uric acid in liquid samples, including urine.
• the test strips include a patch impregnated with a working solution, including stabilized uricase.
• the test strips of the invention are stable in that they can be stored for relatively long periods of time without loss of uricase activity.
• test strips consist of a porous material impregnated with an enzyme-stabilized, pH-controlled, buffered working solution in which uricase is stabilized against thermal degradation.
• the uricase reagent is further protected against degradation during manufacture of the test strips by use of a process consisting of impregnation of the strip with the working solution and drying to remove solvent.
• Application of the working solution may be followed by a second impregnation of the test strip with a concentrated buffer.
• the buffer in the working solution has a salt concentration (using phosphate salt as an example) of about IM and a pH of 8.5 to 9.5, no second application of buffer is required.
• a visually detectable signal indicative of the presence and/or concentration of uric acid present in an analyte sample is incorporated into the test strip.
• the visually detectable signal is produced by a color-forming entity, such as a chromogen.
• Kits incorporating the test strips of the invention are also provided.
• Components of the kits may include test strips, color charts for comparison to color observed after assay performance using the test strips and storage containers for the test strips after use in an assay (for subsequent reference).
• the uric acid detection device of the invention consists of a dry phase test strip impregnated with a stabilized working solution for the semi-quantitative detection of uric acid in a liquid sample.
• the assay is reliable, accurate and trustworthy because the enzyme reagent composition sufficiently maintains its enzymatic and chemical activity over time, provided the instructions on the container to keep the test strips dry are followed (e.g., storage in an air-tight container including a dessicant).
• test strips consist of porous material bound to a non- porous substrate.
• the stabilized working solution is impregnated into an exposed surface of the porous material.
• the working solution is an aqueous solution containing a buffer.
• the buffer in the working solution is one which buffers in the pH range of about 8.5-9.5, preferably about 8.8-9.2 and most preferably at a pH of about 9.0.
• the buffer can generally be any buffer that buffers in these ranges, such as a citrate or phosphate buffer (desirably the latter).
• the phosphate buffer may consist of salts such as salts of potassium, sodium and the like and will have a concentration of salt of at least about IM.
• a working solution having a buffer of a lower pH (6.5 to 7.5, preferably 7.0) and a salt concentration in a range of 50 mM to 2M (preferably 50 mM) may be applied to the test strip, which is then dried. Drying is followed by application of a buffer to the test strip which has a pH within the range of 6.5 to 7.5 (preferably 7.0 pH) and a higher concentration of salt (preferably 200 mM) than is present in the working solution. After the application of concentrated buffer solution, the test strip is again dried. Also included in the working solution is a chromogen which produces a color change on the test strip indicative of the presence of uric acid in the sample.
• uric acid In human urine the first pKa of uric acid is 5.57. At or above a pH of 5.57, uric acid exists mainly as the urate ion which is more soluble than uric acid. At a pH below 5.57, uric acid is the predominant form.
• the enzyme uricase converts urate ions and uric acid to allantoin and hydrogen peroxide. In the presence of an oxidizable chromogen system, this uricase-uric acid reaction produces color.
• the working solution includes both uricase (conveniently of a bacterial source) and an oxidizable chromogen composition.
• an oxidizable chromogen composition suitable for use in the invention is produced by combining a color-forming coupler such as 3,5-dichloro-2- hydroxybenzenesulfonic acid (DHBS) with an oxidizable color developing compound such as 4-aminophenazone to form a chromogen composition which, in the presence of peroxidase, produces a color indicative of the presence of analyte in a sample.
• DHBS 3,5-dichloro-2- hydroxybenzenesulfonic acid
• 4-aminophenazone 4-aminophenazone
• an agent that neutralizes ascorbic acid (frequently found in urine) to prevent its interference with reaction between the uricase in the reagent composition and any uric acid in the sample.
• Appropriate ascorbic acid neutralizers are known in the art and include heavy metal compounds containing cobalt, iron, mercury, or nickel, Co(NH 3 ) 6 Cl 3 , the ferric chelate of N-(hydroxyethyl)-ethylenediaminetriacetic acid, bromate ions, chlorate ions, perchlorate ions, chromate ions, organic peroxides, organic hydroperoxides, organic N-halo compounds or ascorbate oxidase. Ascorbate oxidase oxidizes ascorbic acid to its inert form, dehydroascorbic acid and is a convenient ascorbic acid neutralizer for use in the invention.
• An enzyme stabilizer may also be a component of the working solution.
• an enzyme stabilizer is a surfactant.
• Particularly advantageous surfactants for use in the invention include those described in US Patent No. 3,928,137 (polyoxyalkylene nonionic surfactants having polyoxypropylene chains with a molecular weight between 750 and 6750, constituting 10-80% of the weight of the surfactant), although commonly available surfactants such as Triton X-100, Tween-20, sodium lauryl sarcosinate or polyethylene glycol will also suffice.
• the surfactant serves to both stabilize the enzymes and allow for more uniform coating of the absorbent material with the enzyme reagent composition and hence greater uniformity of color development and improved color differentiation in the test strip before and after contacting with test sample.
• a desirable alternative to a surfactant for use in stabilizing the enzyme component of the working solution is a polysa haride or sugar, such as sucrose (e.g., 0.05% to 10% w/v sucrose), lactose, glucose or the like.
• sucrose e.g., 0.05% to 10% w/v sucrose
• lactose glucose or the like.
• the sugar stabilizes both the uricase and peroxidase enzymes used during preparation of the assay device.
• Bilirubin is frequently found in urine and has the potential to exert negative chemical interference with the peroxidase systems. This problem is obviated in the test strip of the invention by utilizing potassium ferrocyanide as the oxygen acceptor and the DHBS/4-aminophenazone pair as the chromogenic composition. Ferricyanide (produced by oxidation of ferrocyanide in the presence of peroxidase) oxidizes the chromogenic composition. This reaction involves a phenol intermediate that does not react with bilirubin.
• Each of the components of the working solution are mixed in a solvent, preferably a neutral, non-organic solvent such as water or normal saline. Table 1 lists the components and their concentrations in a preferred working solution in which the solvent is distilled water. All of the components of the working solution identified in the Table are commercially available from sources which will be known to, or can be readily ascertained by, those of ordinary skill in the art.
• test strips of the invention may be provided to the end user as part of a kit.
• Components of the kits may include test strips, color charts appropriate to the liquid to be assayed for comparison to color observed after assay performance using the test strips, specimen containers, labels and storage containers for the test strips after use in an assay procedure (for subsequent reference).
• the absorbent material which is impregnated with the working solution can be any substance capable of incorporating the components of the enzyme reagent composition.
• the material must be substantially inert with respect to the enzyme reagent composition and must be porous and/or absorbent relative to the liquid sample to be tested, e.g., urine.
• the substance can be either bibulous matrices or nonbibulous matrices that are insoluble in, and maintain their structural integrity when exposed to, aqueous solutions or physiological fluids.
• Bibulous matrices that can be useful for the devices of the present invention include but are not limited to, paper, sponge materials, cellulose, hydrophilic inorganic powders, wood, synthetic resin fleeces, woven and nonwoven fabrics and like materials.
• Nonlimiting examples of nonbibulous matrices include glass fiber, permeable polymer films and preformed or microporous membranes.
• the enzyme reagent composition is incorporated into the paper by any method such as dipping, spreading or spraying.
• a preferred method of incorporation involves dipping the paper into the working solution then drying to remove the solvent. Drying can be by any method that does not deleteriously affect the reagents incorporated into the absorbent material. The usual drying method is by means of an air oven at 37 to 60°C.
• the absorbent material may be impregnated with a second buffer solution with a pH of about 6.5-7.5, preferably about 7.0, in which the salt of the buffer is more concentrated than the buffer of the working solution.
• the salt concentration of the buffer used in the second impregnation will be 4 times as concentrated; i.e., 200 mM.
• the second impregnation with the concentrated buffer effectively maintains an optimum pH in the device of the invention.
• the pH optimum can be maintained in the device by use of a single working solution treatment, wherein the phosphate buffer has a concentration of at least about IM (up to 2M) and the pH of the buffer is increased to within the range of 8.5 to 9.5, preferably about 9.0.
• the absorbent material is dried again and affixed, via a double-sided adhesive (e.g., two sided adhesive tape), to a solid moisture impervious support.
• This support can be constructed from, for example, hydrophobic plastic, cellulose acetate, polyethylene, terephthalate, polycarbonate, or polystyrene.
• the test strip will consist of a single, working solution- impregnated porous membrane affixed to a solid support having a handle, plastic strip or other means to enable the strip to be handled by the user without contacting the porous membrane.
• the test strips may be constructed in many forms; e.g., as a "dipstick" for immersion into a liquid sample, as an open strip onto which sample is applied dropwise or as an enclosed strip placed inside a cassette housing having ports through which any color change occurring on the strip after addition of analyte may be observed.
• the test strip may be formed of one or more layers of porous material placed in fluid communication with one another.
• a first porous strip may be utilized as a sample receiving zone for immersion in, or receiving dropwise, a liquid analyte sample.
• the sample receiving zone may be placed on the non-porous substrate in fluid communication with a second porous membrane, wherein the latter includes one or more reagent zones, at least one of which will include the working solution of the invention.
• the topmost porous membrane may be coated with gelatin to enhance the life of the strip and clarity of any visible reactions produced in the assay.
• the method of the invention provides a one-step convenient assay for uric acid in a test liquid sample and involves dipping the test strip into the test sample for a time sufficient to saturate the test patch with the sample.
• the test sample can be a biological fluid such as urine, serum, plasma or sweat or a non-biological fluid such as water from some ecological niche, e.g., a river or a lake, or a solution used in a laboratory.
• the test sample is preferably fresh uncentrifuged urine from a mammal, e.g., a human, a non-human primate, a dog, a cat, a cow, a horse, a pig, a sheep, a rabbit, a guinea pig, or a rodent such as a mouse, a rat, or a hamster.
• a mammal e.g., a human, a non-human primate, a dog, a cat, a cow, a horse, a pig, a sheep, a rabbit, a guinea pig, or a rodent such as a mouse, a rat, or a hamster.
• a predetermined time such as 60 seconds to about 5 minutes
• the test strip is examined, either visually or by an instrument, for a response.
• the color transition, if any, of the test patch reveals the presence or concentration of uric acid in the urine sample.
• a color chart bearing color spots corresponding to known concentrations of uric acid can be prepared for the particular enzyme reagent composition used on the test strip.
• the resulting color of the test strip after contact with the test sample can then be compared with the color spots on the chart to determine the concentration of uric acid in the test sample.
• concentration of uric acid in the test sample For example, at uric acid levels of 0 mg/dL, 35 mg/dL, 70 mg/dL and 100 mg/dL the colors produced on the test strip of the invention whose uricase reagent components are described in Table 1 are, respectively, light cream, light pink, magenta and dark magenta.
• test strip can be made quantitative by employing spectrophotometric or colorimetric techniques, as opposed to visual techniques, in order to more reliably and more accurately measure the degree of color transition, and therefore more accurately measure the concentration of uric acid in the liquid test sample, especially at low concentrations such as below 1 mg uric acid/dL of liquid sample.
• IL of a working reagent solution at pH 9.0 were prepared with the following components in dH 2 O: a. Potassium Phosphate, Dibasic Anhydrous IM b. 4-Aminophenazone 30mM c. DHBS 60 mM d. KFeCN 4mM e. Uricase enzyme (Candida utilis) 5KU/ml f. Horseradish Peroxidase lKU/ml g- Ascorbate Oxidase 200 U/ml h. Sucrose 10.0% w/v
• Absorbent paper #593 (Lot # N952) from Schleicher & Schuell were dipped into the above working reagent solution until saturated. The coated paper were then dried in an incubator at 40°C. Double sided adhesive tape from 3M was then applied to one side of the coated dried paper. The paper was then affixed to an inert plastic strip and cut into 5 mm 2 . The squares were stored in an air tight plastic container with desiccant ready for use. C. Preparation of Standards
• Uric acid purchased from Sigma were dissolved in uric acid negative urine base pH 6.5 and value assigned using a marketed liquid reagent Uric Acid Assay (purchased from Teco). The levels assigned to the standards were: 0, 35, 85, 140 mg/dl. The standards were assayed using the above prepared test strips and a picture color chart representing each level was developed and used as reference.
• Uric acid standards were prepared as Example I above at the following pH: 4.5, 5.5, 6.5, 7.5 and 8.5. The standards were then assayed using the test strips prepared from Example I. Corresponding standards from different pH levels produced the same visual result demonstrating that the pH of the patient samples does not affect or interfere with the assay.
• Uric acid standards were prepared as Example I above at a pH of 6.5 and spiked with the following levels of ascorbic acid: 25, 50, 75 and 100 mg/dl. The spiked standards were then assayed using the test strips prepared from Example I above and compared against the color reference chart. No ascorbic acid interference was observed for any of the standards.
• Uric acid standards were prepared as Example I above at a pH of 6.5 and spiked with the following levels of Bilirubin: 10, 20, 30 and 40 mg/dl. The spiked standards were then assayed using the test strips prepared from Example I above and compared against the color reference chart. No Bilirubin interference was observed for any of the standards.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Physics & Mathematics (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Biophysics (AREA)
• Analytical Chemistry (AREA)
• Immunology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Applications Claiming Priority (1)

Publications (2)

Family

ID=22267731

Family Applications (1)

Country Status (4)

Families Citing this family (11)

Citations (2)

Family Cites Families (7)

• 1998
  • 1998-08-06 CA CA002306554A patent/CA2306554A1/en not_active Abandoned
  • 1998-08-06 EP EP98944497A patent/EP1030931A4/de not_active Withdrawn
  • 1998-08-06 WO PCT/US1998/017483 patent/WO2000008207A1/en not_active Application Discontinuation
  • 1998-08-06 AU AU92029/98A patent/AU754237B2/en not_active Ceased

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events